712 related articles for article (PubMed ID: 25915199)
1. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW
Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199
[TBL] [Abstract][Full Text] [Related]
2. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Mao R; Shao J; Zhu K; Zhang Y; Ding H; Zhang C; Shi Z; Jiang H; Sun D; Duan W; Luo C
J Med Chem; 2017 Jul; 60(14):6289-6304. PubMed ID: 28650658
[TBL] [Abstract][Full Text] [Related]
3. EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
Liu X; He J; Mao L; Zhang Y; Cui W; Duan S; Jiang A; Gao Y; Sang Y; Huang G
Exp Eye Res; 2021 Jan; 202():108286. PubMed ID: 33035554
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
[TBL] [Abstract][Full Text] [Related]
6. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
7. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
9. Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R
Blood Adv; 2024 Jan; 8(1):150-163. PubMed ID: 37782774
[TBL] [Abstract][Full Text] [Related]
10. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations.
Tao H; Yan X; Zhu K; Zhang H
Chem Pharm Bull (Tokyo); 2019; 67(4):382-388. PubMed ID: 30930442
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F; Hwang I; Sloan S; Hinterschied C; Helmig-Mason J; Long M; Chan WK; Prouty A; Chung JH; Zhang Y; Singh S; Youssef Y; Bhagwat N; Chen Z; Chen-Kiang S; Di Liberto M; Elemento O; Sehgal L; Alinari L; Vaddi K; Scherle P; Lapalombella R; Paik J; Baiocchi RA
Blood Adv; 2023 Oct; 7(20):6211-6224. PubMed ID: 37327122
[TBL] [Abstract][Full Text] [Related]
13. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
[TBL] [Abstract][Full Text] [Related]
14. Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor.
Rioux N; Duncan KW; Lantz RJ; Miao X; Chan-Penebre E; Moyer MP; Munchhof MJ; Copeland RA; Chesworth R; Waters NJ
Xenobiotica; 2016; 46(3):268-77. PubMed ID: 26294260
[TBL] [Abstract][Full Text] [Related]
15. Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.
Kong GM; Yu M; Gu Z; Chen Z; Xu RM; O'Bryant D; Wang Z
PLoS One; 2017; 12(8):e0181601. PubMed ID: 28806746
[TBL] [Abstract][Full Text] [Related]
16. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
18. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
19. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
20. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
Gullà A; Hideshima T; Bianchi G; Fulciniti M; Kemal Samur M; Qi J; Tai YT; Harada T; Morelli E; Amodio N; Carrasco R; Tagliaferri P; Munshi NC; Tassone P; Anderson KC
Leukemia; 2018 Apr; 32(4):996-1002. PubMed ID: 29158558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]